Liraglutide did not reverse cognitive deficits in a rat model of sporadic Alzheimer's disease and actually worsened fear-motivated memory, despite partially restoring some gene expression changes — adding a note of caution to enthusiasm about GLP-1 drugs for dementia.
Memory worsenedLiraglutide not only failed to improve spatial learning in Alzheimer's model rats but actually worsened fear-motivated memory performance, despite partially correcting brain metabolic gene expression
What the researchers found
In rats with STZ-induced brain insulin resistance (a model of sporadic Alzheimer's):
• STZ-icv rats showed impaired spatial learning (Morris water maze), fear-motivated memory deficits (passive avoidance), reduced hippocampal neurogenesis, and downregulated insulin/glucose metabolism genes
• 4 weeks of liraglutide (0.3 mg/kg subcutaneous) did NOT reverse spatial learning deficits in the Morris water maze
• Liraglutide WORSENED passive avoidance performance (fear-motivated memory)
• Liraglutide partially restored dysregulated gene expression in hippocampus and prefrontal cortex related to insulin signaling and glucose metabolism
• However, liraglutide additionally stimulated neuroinflammation — potentially counteracting its beneficial gene expression effects
Why it matters
With clinical trials of GLP-1 drugs for Alzheimer's underway, this preclinical study provides a cautionary counterpoint. The finding that liraglutide worsened one type of memory and stimulated neuroinflammation — even while partially correcting metabolic gene expression — suggests that the relationship between GLP-1 signaling and brain function is more complex than simple insulin sensitization. These results could inform clinical trial design and patient selection.
How the study worked
Male Wistar rats received intracerebroventricular streptozotocin (3 mg/kg) or vehicle to induce an insulin-resistant brain state. Two months later, subcutaneous liraglutide (0.3 mg/kg) or vehicle was given daily for 4 weeks. Cognitive testing included the Morris water maze (spatial learning) and passive avoidance test (fear-motivated memory). Adult neurogenesis was quantified by immunohistochemistry. Gene expression for insulin signaling, glucose uptake, and neuroinflammation pathways was measured by quantitative real-time PCR in hippocampus and prefrontal cortex.
What this study cannot tell us
Single dose level tested (0.3 mg/kg) — the authors acknowledge that refined dosing might yield different results. Treatment started 2 months after disease induction, which represents established disease rather than prevention. The STZ-icv model, while well-accepted, may not fully replicate human sporadic Alzheimer's. Only male rats were used. The 4-week treatment duration may be insufficient for full therapeutic effect. The specific neuroinflammatory pathways activated were not fully characterized.
How to read the evidence
This is a preclinical study in a well-accepted rat model of sporadic Alzheimer's disease. The experimental design includes appropriate controls and multiple outcome measures (behavioral, histological, molecular). However, negative preclinical results in one model do not necessarily predict human outcomes, and the authors note that refined dosing may yield different results.
When this study was published
Published in 2025, this is a very current study that provides timely counterbalance to the prevailing optimism about GLP-1 drugs for Alzheimer's. Several clinical trials of GLP-1 agonists for dementia are ongoing and will provide definitive human data.
The bigger picture
GLP-1 drugs are being explored for an expanding list of neurological conditions including Alzheimer's, Parkinson's, and depression. Most of the excitement comes from epidemiological data and mouse models showing cognitive benefits. This study in a different (and arguably more clinically relevant) rat model of sporadic Alzheimer's provides a reality check. The dual finding — metabolic gene correction but increased neuroinflammation — highlights the need for careful evaluation before assuming GLP-1 drugs will automatically benefit the brain.
Questions still open
- Would different doses, timing, or duration of liraglutide produce cognitive benefits rather than harm in this model?
- Does the neuroinflammation triggered by liraglutide counteract its metabolic gene restoration effects in the brain?
- How do these negative results in a sporadic AD rat model reconcile with positive findings in transgenic AD mouse models?
Common questions
Does this mean GLP-1 drugs can't help with Alzheimer's?
Why would a diabetes drug potentially worsen memory?
Read the original research
Approaching therapy of Alzheimer's disease via the antidiabetic drug liraglutide-a study with streptozotocin intracerebroventricularly treated Wistar rats.
Journal of neural transmission (Vienna, Austria : 1996), 132(10), 1587-1608
Citation
Knezovic, Ana; Hosch, Michael; Hamann, Catharina Sophia; Popp, Sandy; Ortega, Gabriela; Osmanovic-Barilar, Jelena; Grünblatt, Edna; Monoranu, Camelia; Riederer, Peter; Salkovic-Petrisic, Melita; Schmitt-Böhrer, Angelika. (2025). Approaching therapy of Alzheimer's disease via the antidiabetic drug liraglutide-a study with streptozotocin intracerebroventricularly treated Wistar rats.. Journal of neural transmission (Vienna, Austria : 1996), 132(10), 1587-1608. https://doi.org/10.1007/s00702-025-02979-z